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Abstract 
 
Background: While RSV circulation results in high burden of hospitalization, particularly 
among infants, young children and the elderly, little is known about the role of different 
age groups in propagating annual RSV epidemics in the community. 
 
Methods: During a communicable disease outbreak, some subpopulations may play a 
disproportionate role during the outbreak's ascent due to increased susceptibility and/or 
contact rates. Such subpopulations can be identified by considering the proportion that 
cases in a subpopulation represent among all cases in the population occurring before 
(Bp) and after the epidemic peak (Ap) to calculate the subpopulation's relative risk, 
RR=Bp/Ap. We estimated RR for several age groups using data on RSV 
hospitalizations in the US between 2001-2012 from the Healthcare Cost and Utilization 
Project (HCUP). 
 
Results: Children aged 3-4y and 5-6y each had the highest RR estimate for 5/11 
seasons in the data, with RSV hospitalization rates in infants being generally higher 
during seasons when children aged 5-6y had the highest RR estimates. Children aged 
2y had the highest RR estimate during one season. RR estimates in infants and 
individuals aged 11y and older were mostly lower than in children aged 1-10y.  
 
Conclusions: The RR estimates suggest that preschool and young school-age children 
have the leading relative roles during RSV epidemics. We hope that those results will 
aid in the design of RSV vaccination policies. 
 
 
Introduction 
 
Annual RSV epidemics take place in the US, exerting a heavy toll in severe outcomes in 
infants and young children [1-4], with rates of associated bronchiolitis hospitalizations in 
infants being particularly high [5,6]. Rates of hospitalizations with RSV present in the 
diagnosis drop off dramatically with age ([7], Table 1 – see also Table 1 in our paper), 
but those represent only a fraction of all hospitalizations associated with RSV infections 
[8], and our understanding of the hospitalization burden stemming from the circulation of 
the respiratory syncytial virus is limited, particularly for the adult populations [9,10]. 
Previous work [11] showed high rates of RSV-associated respiratory hospitalizations 
among older adults (see also [7] and [12]). 
 
Given the high burden of severe outcomes associated with RSV, it would be useful to 
understand the roles of different population groups in propagating RSV epidemics in the 
community. Such information should contribute to our overall understanding of RSV 
epidemiology that should help inform mitigation efforts, with a variety of RSV vaccine 
candidates for different populations being in different stages of development [13,14]). 
 
In [15-17] we developed a method for assessing the roles of different subpopulations in 
transmission during epidemics of infectious diseases. The idea of that method is that 
subpopulations that play a disproportionate role during the outbreak's ascent due to 
increased susceptibility and/or contact rates can be related to the relative risk (RR) 
statistic that evaluates the change in the subpopulation’s proportion among all cases in 
the population before vs. after the epidemic’s peak (see Methods). In [15], we have 
estimated the RR statistic in select age groups for several influenza epidemics in the US 
using data on hospitalized cases for the inference. An important aspect of the method 
proposed in [15] is that the results do not depend on case-hospitalization rates in 
different age groups. Moreover, we have used simulations to show a relation between a 
higher value for an RR statistic in a given age group and a higher impact of vaccinating 
an individual in that age group on reducing the epidemic’s initial growth rate. 
 
In this paper we estimate the RR statistic in different age groups for eleven RSV 
epidemics in the US using data on RSV hospitalizations in a collection of US states 
between 2001 and 2012 [18]. We consider a fine age stratification for young children to 
examine how their role during RSV epidemics changes with age progression. We 
compare the RR estimates in different age groups across eleven RSV epidemics and 
discuss the relevance of our findings to the study of a potential impact of vaccination.	
 
 
Methods 
 
Data  
We used weekly data on hospitalizations with an RSV diagnosis (both primary and 
contributing [ICD-9] codes 079.6, 466.11, 480.1) from the State Inpatient Databases of 
the Healthcare Cost and Utilization Project (HCUP), maintained by the Agency for 
Healthcare Research and Quality through an active collaboration [18]. This database 
contains hospital discharges from community hospitals in participating states. We 
compiled data for the 2001-2002 through the 2011-2012 RSV seasons for 10 different 
age groups and 26 participating states (representing about 54.3% of the US population 
between 2001-2012) that reported continuously to HCUP between week 27, 2001 and 
week 26, 2012. Those states are: AZ,	CA,	CO,	CT,	GA,	IA,	IL,	KY,	MD,	MN,	MO,	NC,	NE,	NJ,	NV,	OH,	OR,	RI,	SC,	SD,	TN,	UT,	VT,	WA,	WI,	WV. Each RSV season was defined as a 
period between calendar week 27 of one year through calendar week 26 on the next 
year. One year (2006) had 53 calendar weeks; the corresponding season was defined 
as the period from week 27 of 2006 through week 25 of 2007.  
 
Before-and-after the peak counts  
Data on the cumulative number/rate per 100,000 of RSV hospitalizations in different age 
groups during each season (Table 1) suggest the following age splitting (in years) for 
the analysis: (<1,1,2,3-4,5-6,7-10,11-17,18-49,50-64,65+). For each season and each 
state !, we defined the peak week ! !  for that state as the calendar week with the 
highest total number of RSV hospitalizations in the state. Each case in the state during 
the given season was classified as before-the-peak case if it occurred in or prior to week ! ! − 2; after-the-peak case if it occurred in or after week ! ! + 2. We exclude cases 
occurring between weeks ! ! − 1 and ! ! + 1 from the analysis to avoid 
misclassification of counts as before or after-the-peak stemming from the noise in the 
count data for the hospitalized cases, differences in case-hospitalization rates 
(proportion of RSV infections that result in hospitalizations with an RSV diagnosis) for 
the various age groups that may result in different peak times for the counts of the 
hospitalized cases vs. cases of infection in the community, etc. 
 
For each age group !, before-and-after the peak seasonal counts in that age group in 
different states were combined into national before-and-after the peak counts !(!) and !(!) correspondingly.  
 
Statistical Inference 
The point estimate for the seasonal relative risk !!(!) in an age group ! is 
                                               !(!)!(ℎ)! !(!)!(ℎ)!   
   
The estimates and confidence bounds for relative risks in each group were obtained in a 
Bayesian framework following the methodology in [10]. Briefly, as the number of cases 
of infection in each age group is large and case-hospitalization rates (see the previous 
sub-section) are low, we assume that the numbers of reported cases in each age group 
before an after the peak are Poisson distributed. Posterior samples for the Poisson 
parameters (with a flat prior) corresponding to the counts ! ℎ ,!(ℎ) are generated; for 
each i=1,..,100000, the corresponding parameters !! ℎ ,!!(ℎ) are plugged into the 
equation above to generate an estimate !!!(!) for the relative risk. The mean and the 
credible interval for the sample (!!! ! ) (i=1,..,100000) are then extracted. 
 
 
Results 
 
Table 1 presents the cumulative number and the rate per 100,000 of RSV 
hospitalizations during each season in each age group for the 26 states that reported 
continuously between the 2001-2002 through 2011-2012 seasons (Methods). There is 
an apparent upward trend in the counts/rates in all age groups over 3 years of age 
(being most pronounced in adults), likely indicative of temporal changes in 
detection/diagnostic practices. We note that differences in hospitalization counts/rates 
by age need not correspond to differences in RSV infection rates by age – see also the 
1st paragraph of the Discussion. 
 
 
 
 
Age / 
Season 
2001
-02 
2002
-03 
2003
-04 
2004
-05 
2005
-06 
2006
-07 
2007
-08 
2008
-09 
2009
-10 
2010
-11 
2011
-12 
<1y 44855
/2049	
38518
/1766	
40855
/1856	
34133
/1546	
38272
/1725	
38346
/1697	
39289
/1721	
34462
/1542	
37810
/1734	
37126
/1715	
28692
/1334	
1y 8677/
400.9	
7245/
331.4	
8213/
377.9	
7040/
321.5	
7436/
338.5	
7372/
334.4	
7986/
356.2	
7328/
324.2	
8921/
402.9	
8775/
403.3	
6757/
311	
2y 2825/
134	
2267/
104.8	
2713/
124.2	
2343/
108	
2637/
120.4	
2485/
113.1	
2869/
130.2	
2690/
120.1	
3601/
159.3	
3645/
164.3	
2801/
128.4	
3y 1059/
50.6	
908/	
43	
1128/
52.1	
930/	
42.6	
1069/
49.1	
1038/
47.3	
1112/
50.4	
1220/
55.1	
1727/
76.9	
1764/
78	
1364/
61.4	
4y 437/	
20.8	
351/	
16.7	
526/	
24.8	
476/	
21.9	
465/	
21.1	
419/	
19.1	
490/	
22.1	
489/	
22	
790/	
35.3	
829/	
36.7	
661/	
29.2	
5y 209/	
9.8	
161/	
7.6	
226/	
10.7	
207/	
9.7	
233/	
10.7	
197/	
8.9	
237/	
10.7	
274/	
12.3	
399/	
17.8	
452/	
20.1	
320/	
14.1	
6y 118/	
5.4	
88/	
4.1	
116/	
5.5	
102/	
4.9	
117/	
5.5	
109/	
5	
133/	
6	
146/	
6.6	
209/	
9.4	
257/	
11.5	
200/	
8.9	
7y 66/	
3	
56/	
2.6	
58/	
2.7	
66/	
3.1	
61/	
2.9	
57/	
2.7	
67/	
3.1	
96/	
4.3	
124/	
5.6	
160/	
7.2	
88/	
3.9	
8y 48/	
2.2	
44/	
2	
36/	
1.6	
34/	
1.6	
42/	
2	
45/	
2.1	
45/	
2.1	
51/	
2.3	
73/	
3.3	
88/	
4	
76/	
3.4	
9y 40/	
1.8	
24/	
1.1	
20/	
0.9	
29/	
1.3	
36/	
1.7	
36/	
1.7	
44/	
2.1	
49/	
2.3	
85/	
3.8	
55/	
2.5	
34/	
1.5	
10y 31/	
1.3	
28/	
1.2	
36/	
1.6	
24/	
1.1	
35/	
1.5	
32/	
1.4	
37/	
1.6	
43/	
1.9	
55/	
2.4	
57/	
2.5	
48/	
2.1	
11y 33/	
1.4	
27/	
1.2	
19/	
0.8	
25/	
1.1	
31/	
1.4	
19/	
0.8	
19/	
0.8	
38/	
1.7	
48/	
2.1	
60/	
2.6	
40/	
1.7	
12-17y 106/	
0.8	
84/	
0.6	
106/	
0.8	
81/	
0.6	
109/	
0.8	
116/	
0.8	
142/	
1	
151/	
1.1	
194/	
1.4	
218/	
1.6	
149/	
1.1	
18-49y 191/	
0.3	
132/	
0.2	
177/	
0.2	
150/	
0.2	
238/	
0.3	
235/	
0.3	
318/	
0.4	
373/	
0.5	
493/	
0.7	
568/	
0.8	
465/	
0.6	
50-64y 156/	
0.7	
120/	
0.5	
144/	
0.6	
162/	
0.6	
267/	
1	
219/	
0.8	
320/	
1.1	
328/	
1.1	
616/	
2	
723/	
2.2	
564/	
1.7	
65+y 297/	
1.6	
190/	
1	
252/	
1.3	
190/	
1	
406/	
2.1	
327/	
1.7	
573/	
2.8	
663/	
3.2	
950/	
4.5	
1331/
6.2	
1174/
5.3	
 
Table 1: Seasonal counts and rates per 100,000 for hospitalizations with RSV 
mentioned in the diagnosis in select age groups (in years). Data from the State Inpatient 
Databases of the Healthcare Cost and Utilization Project [18]. 
 
Tables 2 and 3 present the seasonal estimates of the relative risks in select age groups. 
Children aged 3-4y and 5-6y each had the highest RR estimate for 5/11 seasons in the 
data, with RSV hospitalization rates in infants being generally higher during seasons 
when children aged 5-6y had the highest RR estimates (Tables 1,2). Children aged 2y 
had the highest RR estimate during one season, with RR estimates in children aged 2y 
being higher than the ones in children aged 1y in 9/11 seasons. RR estimates in infants 
and individuals aged 11y and older were mostly lower than in children aged 1-10y. 
 
Season / 
Age 
<1 1y 2y 3-4y 5-6y 
2001-02 0.964	
(0.95,0.97)	
1.172	
(1.12,1.23)	
1.181	
(1.08,1.28)	
1.146	
(1.01,1.29)	
1.284	
(0.99,1.64)	
2002-03 0.94	
(0.93,0.95)	
1.211	
(1.15,1.27)	
1.33	
(1.21,1.46)	
1.312	
(1.16,1.48)	
1.41	
(1.06,1.85)	
2003-04 0.93	
(0.92,0.94)	
1.206	
(1.15,1.26)	
1.272	
(1.17,1.39)	
1.396	
(1.24,1.57)	
2.103	
(1.6,2.73)	
2004-05 0.945	
(0.93,0.96)	
1.121	
(1.07,1.18)	
1.369	
(1.25,1.5)	
1.408	
(1.25,1.58)	
1.363	
(1.04,1.76)	
2005-06 0.935	
(0.92,0.95)	
1.194	
(1.14,1.25)	
1.476	
(1.35,1.62)	
1.534	
(1.36,1.73)	
1.386	
(1.08,1.76)	
2006-07 0.949	
(0.94,0.96)	
1.164	
(1.11,1.22)	
1.29	
(1.18,1.41)	
1.473	
(1.31,1.65)	
1.398	
(1.09,1.77)	
2007-08 0.963	
(0.95,0.97)	
1.184	
(1.13,1.24)	
1.296	
(1.19,1.41)	
1.217	
(1.08,1.36)	
1.176	
(0.93,1.47)	
2008-09 0.989	
(0.98,1)	
1.113	
(1.06,1.17)	
1.104	
(1.01,1.2)	
1.19	
(1.07,1.32)	
0.978	
(0.78,1.21)	
2009-10 0.905	
(0.89,0.92)	
1.271	
(1.21,1.33)	
1.259	
(1.17,1.35)	
1.504	
(1.37,1.65)	
1.721	
(1.42,2.08)	
2010-11 0.973	
(0.96,0.99)	
1.164	
(1.11,1.22)	
1.215	
(1.13,1.31)	
1.35	
(1.23,1.48)	
1.391	
(1.16,1.65)	
2011-12 0.942	
(0.93,0.96)	
1.178	
(1.12,1.24)	
1.297	
(1.19,1.41)	
1.425	
(1.29,1.57)	
1.22	
(1,1.48)	
 
Table 2: Seasonal RR estimates for select age groups (children under 7y) for RSV 
epidemics between 2001-2012 (Methods). Data from the State Inpatient Databases of 
the Healthcare Cost and Utilization Project [18]. 
 
 
 
 
 
 
Season / 
Age 
7-10y 11-17y 18-49y 50-64y 65+y 
2001-02 0.733	
(0.51,1.01)	
0.738	
(0.5,1.05)	
0.65	
(0.46,0.89)	
0.926	
(0.62,1.33)	
0.382	
(0.28,0.51)	
2002-03 0.953	
(0.66,1.33)	
1.089	
(0.7,1.62)	
0.973	
(0.66,1.39)	
0.929	
(0.62,1.34)	
0.812	
(0.57,1.13)	
2003-04 1.732	
(1.17,2.49)	
1.599	
(1.02,2.42)	
0.816	
(0.57,1.12)	
0.993	
(0.68,1.41)	
1.053	
(0.8,1.36)	
2004-05 1.34	
(0.92,1.89)	
1.014	
(0.65,1.5)	
0.739	
(0.5,1.05)	
0.748	
(0.51,1.06)	
0.605	
(0.42,0.84)	
2005-06 1.178	
(0.82,1.65)	
0.869	
(0.57,1.27)	
0.711	
(0.53,0.94)	
0.606	
(0.46,0.79)	
0.584	
(0.46,0.73)	
2006-07 1.294	
(0.92,1.78)	
0.757	
(0.49,1.1)	
0.693	
(0.51,0.92)	
0.48	
(0.34,0.65)	
0.493	
(0.37,0.64)	
2007-08 0.946	
(0.67,1.29)	
0.718	
(0.49,1.01)	
0.516	
(0.39,0.67)	
0.57	
(0.43,0.74)	
0.389	
(0.31,0.48)	
2008-09 1.139	
(0.84,1.51)	
0.612	
(0.43,0.84)	
0.566	
(0.44,0.71)	
0.566	
(0.43,0.72)	
0.511	
(0.42,0.61)	
2009-10 1.636	
(1.26,2.09)	
1.124	
(0.82,1.5)	
0.822	
(0.67,1)	
0.747	
(0.62,0.89)	
0.61	
(0.52,0.71)	
2010-11 1.031	
(0.8,1.3)	
0.749	
(0.56,0.98)	
0.578	
(0.47,0.7)	
0.593	
(0.5,0.7)	
0.413	
(0.36,0.47)	
2011-12 1.359	
(1.02,1.79)	
0.884	
(0.63,1.21)	
0.847	
(0.69,1.03)	
0.591	
(0.49,0.71)	
0.596	
(0.52,0.68)	
 
Table 3: Seasonal RR estimates for select age groups (individuals over the age of 7y) 
for RSV epidemics between 2001-2012 (Methods). Data from the State Inpatient 
Databases of the Healthcare Cost and Utilization Project [18].  
 
 
Discussion 
 
Annual RSV epidemics in the US exert a heavy burden of severe disease in young 
children, particularly infants [1-4]. High rates of RSV-associated hospitalization were 
also estimated for the elderly [7,11,12]. At the same time, as disease severity is highly 
age-specific, there is limited information about the differences in RSV infection rates by 
age, and the role that the different age groups play in the dynamics of RSV infections in 
the community. In this paper we examine the role of different age groups in propagating 
annual RSV epidemics in the US using the RR statistic introduced in our earlier work 
[15-17], with values for that statistic in various age groups related to the impact of 
vaccination of individuals in those age groups on the epidemic’s initial growth rate. Our 
results suggest that the highest estimates for the RR statistic belonged to either children 
aged 3-4y or 5-6y for most RSV epidemics. Moreover, rates of hospitalizations in infants 
with RSV present in the diagnosis were generally higher during those seasons when 
children aged 5-6y had the highest estimate for the RR statistic. The estimates for the 
RR statistic for infants and individuals over the age of 11y were generally lower than the 
ones for children aged 1-10y.  
 
While several vaccine candidates for the infant and the pediatric populations are 
currently in different stages of development [13,14], the schedule for RSV vaccine 
administration in non-infant populations is unclear. Such schedule should account for 
both the direct protection imparted by vaccines, as well as the impact of vaccination on 
RSV transmission in the community. We hope that our study makes a contribution 
towards examining those issues, particularly in pointing to the prominence of children 
aged 3-6y during RSV epidemics.  
 
The estimate of the relative role of infants under one year of age may be skewed by 
several factors. First, the immunological status of some infants changes through the 
course of RSV epidemics due to the waning immunity rendered by maternal antibodies 
[19-21]. Secondly, their population changes during the course of the outbreak through 
new births and ageing, namely infants who are close to the age of one at the start of the 
outbreak would be over the age of one during the outbreak’s descent. Both phenomena 
would distribute infections among infants more uniformly during the epidemic periods 
and bias the estimates of the RR statistic toward the null value of 1. While we cannot 
estimate the magnitude of that bias from the available data, we note that the value of 
the RR statistic for infants is consistently under 1 (Table 2), with values over 1 for the 
leading driver groups. This combination of RR estimates below 1 and biases towards 
the null value of 1 for infants makes it seem unlikely that in the absence of biases, the 
values of the RR statistic in infants during different seasons would be as high as those 
for the leading driver groups. One possible explanation behind the relatively low RR 
estimates for infants is that infants, while potentially exceptionally susceptible to 
infection, have limited contacts, particularly with their peers, compared with other 
children, with outbreaks in daycare, school, and other setting where those children 
interact likely contributing to the prominence of those children during RSV epidemics as 
suggested by our estimates. 
 
Our study has some additional limitations. The relation between the RR statistic and the 
role played by an average individual in a given age group in transmission dynamics is 
not entirely clear. Our earlier work ([15,16]) had attempted to address this issue through 
simulations of transmission dynamics, finding an association between the RR statistic in 
a given age group and the impact of vaccination of an individual in that age group on the 
epidemic’s initial growth rate/reproductive number. While we have used state-specific 
peaks of RSV hospitalizations to characterize the before-vs.-after the peak cases, 
further asynchrony in RSV epidemics within each state may make this categorization of 
some cases for the corresponding local outbreaks inaccurate. We note that this would 
bias all the RR estimates toward the null value of 1, whereas the data allows for a 
delineation of the driver groups. For the 2003-04 and 2009-10 seasons (that had the two 
largest influenza epidemics during the study period), values of the RR statistic for RSV 
epidemics for school-age children were the highest during the study period. There are 
several possible explanations for this including immunological interference between 
influenza and RSV, and changes in diagnosis/laboratory testing practices through the 
course of a season, possibly stemming from changes in perception regarding the 
potential viral etiologies for the hospitalized cases. The latter might introduce a bias in 
the RR estimates for a number of RSV seasons, and the scope of that bias is difficult to 
assess with the available data. We also note that annual rates of RSV hospitalization in 
different age groups (Table 1) suggest temporal (year-to-year) changes in testing 
practices; however this should not bias the RR estimates that are derived separately 
during each season, unless testing/diagnostic practices change through the course of 
the season in a manner that is not uniform for all age groups [15,17]. 
 
We believe that despite the above limitations, our study sheds new light on the role of 
different age groups during RSV epidemics, a subject that had received limited attention 
in the literature. It suggests the prominence of children aged 3-6y in propagating RSV 
epidemics, pointing to the potential benefit of RSV vaccine administration in that age 
group for mitigating RSV epidemics in the community.  
 
 
Acknowledgement: We would like to thank the HCUP Partner states that voluntarily 
provide their data to the project, and without whom this research would not be possible 
(https://www.hcup-us.ahrq.gov/partners.jsp). We are also grateful to Zeynal Karaca, 
PhD, and Jenny Schnaier who helped us with this project on behalf of AHRQ. 
 
 
References 
 
 
1. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, et al. (2016) Defining    
           the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection   
           Among Infants and Children in Western Countries. Infect Dis Ther. 5(3):271-98 
2. US CDC. Respiratory Syncitial Virus Infection. 
http://www.cdc.gov/rsv/about/infection.html. 
3. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, et al. (2009) The   
           burden of respiratory syncytial virus infection in young children. N Engl J Med.   
           360(6):588-98 
4. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, et al. (2013)  
           Respiratory syncytial virus-associated hospitalizations among children less than  
           24 months of age. Pediatrics 132(2):e341-8 
5. Faber TE, Kimpen JL, Bont LJ (2008) Respiratory syncytial virus bronchiolitis: 
prevention and treatment. Expert Opin Pharmacother 9: 2451-2458. 
6. Moreno MA (2009) Advice for patients. Bronchiolitis and respiratory syncytial virus. 
Arch Pediatr Adolesc Med 163: 1072. 
7. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, et al. (2012) 
Hospitalizations associated with influenza and respiratory syncytial virus in the 
United States, 1993-2008. Clin Infect Dis 54: 1427-1436. 
8. Simonsen L, Viboud C (2012) The art of modeling the mortality impact of winter-
seasonal pathogens. J Infect Dis 206: 625-627. 
9. Gilca R, De Serres G, Skowronski D, Boivin G, Buckeridge DL (2009) The need for 
validation of statistical methods for estimating respiratory virus-attributable 
hospitalization. Am J Epidemiol 170: 925-936. 
10. Branche AR, Falsey AR. (2015) Respiratory syncytial virus infection in older adults: 
an under-recognized problem.. Drugs Aging. 32(4):261-9  
11. Goldstein E, Greene SK, Olson DR, Hanage WP, Lipsitch M (2015) Estimating the 
hospitalization burden associated with influenza and respiratory syncytial virus in 
New York City, 2003-2011. Influenza Other Respir Viruses 9: 225-233. 
12. Falsey AR1, Walsh EE. (2000) Respiratory syncytial virus infection in adults. Clin 
Microbiol Rev. 13(3):371-84. 
13. Broadbent L, Groves H, Shields MD, Power UF (2015) Respiratory syncytial virus, 
an ongoing medical dilemma: an expert commentary on respiratory syncytial 
virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. 
Influenza Other Respir Viruses 9: 169-178. 
14. PATH publications. RSV Vaccine and mAb Snapshot. Dec. 2016.   
http://www.path.org/vaccineresources/files/RSV-snapshot-December2016.pdf  
15. Worby CJ, Chaves SS, Wallinga J, Lipsitch M, Finelli L, et al. (2015) On the relative 
role of different age groups in influenza epidemics. Epidemics 13: 10-16. 
16. Worby CJ, Kenyon C, Lynfield R, Lipsitch M, Goldstein E (2015) Examining the role 
of different age groups, and of vaccination during the 2012 Minnesota pertussis 
outbreak. Sci Rep 5: 13182. 
17. Goldstein E, Pitzer VE, O'Hagan JJ, Lipsitch M. Temporally Varying Relative Risks 
for Infectious Diseases: Implications for Infectious Disease Control. Epidemiology. 
2017;28(1):136-144  
18. SID Database Documentation. Healthcare Cost and Utilization Project (HCUP). 
Agency for Healthcare Research and Quality, Rockville, MD. April 2017. 
https://www.hcup-us.ahrq.gov/db/state/siddbdocumentation.jsp 
19. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S (1981) Maternal antibody and 
respiratory syncytial virus infection in infancy. J Med Virol 7: 263-271. 
20. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, et al. (2009) The level and 
duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One 4: 
e8088. 
21. Hacimustafaoglu M, Celebi S, Aynaci E, Sinirtas M, Koksal N, et al. (2004) The 
progression of maternal RSV antibodies in the offspring. Arch Dis Child 89: 52-53. 
 
